GIS
28
2
WU
22
2
STI
17
10
R
75
3
TROW
54
-8
NOC
54
4
TEL
71
3
BAX
36
-5
IFF
53
5
URI
72
3
ILMN
46
-4
CFG
68
-2
RCL
87
4
MPC
44
3
XYL
41
4
ADM
17
-3
SYY
49
2
CA
22
12
WMB
71
3
VFC
62
-3
GIS
28
2
WU
22
2
STI
17
10
R
75
3
TROW
54
-8
NOC
54
4
TEL
71
3
BAX
36
-5
IFF
53
5
URI
72
3
ILMN
46
-4
CFG
68
-2
RCL
87
4
MPC
44
3
XYL
41
4
ADM
17
-3
SYY
49
2
CA
22
12
WMB
71
3
VFC
62
-3
Financhill
Back

Celldex Therapeutics 10K Form

Sell
31

CLDX
Celldex Therapeutics

Last Price:
26.24
Seasonality Move:
15.2%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CLDX News And Ratings

See the #1 stock for the next 7 days that we like better than CLDX

CLDX Financial Statistics

Sales & Book Value

Annual Sales: $6.88M
Cash Flow: $-55.88M
Price / Cash Flow: 0
Annual Sales: $11.85
Price / Book: 2.21

Profitability

EPS (TTM): -2.58000
Net Income (TTM): $-154.08M
Gross Margin: $0
Return on Equity: -24.74%
Return on Assets: -23.46%

Celldex Therapeutics Earnings Forecast

Key Celldex Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 30 years for CLDX is 0.00%.
  • The Selling, General & Administrative Expenses for CLDX have been equal to 449.14% of Gross Profit Margin.
  • The Research & Development expenses have been 1,714.53% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of CLDX is -2,054.76% of Total Revenues.
  • Per Share Earnings over the last 38 years have been positive in 22 years.

Celldex Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CLDX
CUSIP: 15117B
Website: celldex.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 24.27
Quick Ratio: 23.58

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CLDX Technical Analysis vs Fundamental Analysis

Sell
31
Celldex Therapeutics (CLDX) is a Sell

Is Celldex Therapeutics a Buy or a Sell?